Lucid Group has appointed Frances O’Connor as client partnership director at its strategic health communications and medical education firm Leading Edge.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.